View All

 

"Sprayer" to Prevent Thrombosis

This is a HIA partner technology

Samir Kapadia, MD

A device that increases blood flow to the left atrial appendage via a “sprayer”. This sprayer is a tube that begins in the left appendage and directs a portion of the blood flow directly into the left atrial appendage.


Anti-CEP Therapeutic for Age Related Macular Degeneration

Anti-CEP Therapeutic for Age Related Macular Degeneration

This is a HIA partner technology

John W. Crabb, PhD; Robert G. Salomon, PhD; Bela Anand-Apte, MD, PhD; Quteba Ebrahem, MD; Kutralanathan Regnathan

Wet macular degeneration is the advanced stage of age-related macular degeneration (AMD) and affects approximately 10-15% of patients with AMD, yet accounts for more than 80% of all vision loss associated with the disease. Wet AMD is caused by abnormal blood vessel growth in the retina, known as choroidal neovascularization.


Application of Mitotic Kinesin Targeting Strategies to the Treatment of Anaplastic Gliomas

Application of Mitotic Kinesin Targeting Strategies to the Treatment of Anaplastic Gliomas

This is a HIA partner technology

Steven Rosenfeld, MD, PhD; Jeremy Rich, MD; Monica Venere, PhD

Mitotic kinesins are motor proteins required to facilitate proper cell division (mitosis).  Recent studies by Dr. Rosenfeld and his team have shown that one of these kinesins, Eg5, is up-regulated in tumor cells from human glioblastomas. 


AppointmentPass™

AppointmentPass™

This is a HIA partner technology

John Bona

AppointmentPass™ is a technology that creates efficiency in the appointment check-in process. It is comprised of proprietary software coupled with off the shelf tablets and kiosk hardware. 


Aptamers for Tumor Initiating Cells

Aptamers for Tumor Initiating Cells

This is a HIA partner technology

Jeremy Rich, MD; Youngmi Kim; Anita Hjelmeland, PhD

Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule.  Dr. Rich and his team have developed aptamers consisting of a single stranded nucleic acids having 100 nucleotides or less that specifically binds to tumor initiating cancer cells, identified by screening a large pool of randomly generated aptamers to obtain a discrete set of them that specifically bind to tumor initiating cancer cells, such as those found in brain cancer or glioblastoma.


Autologous C5 Vaccines For Treating Complement-Mediated Diseases

Autologous C5 Vaccines For Treating Complement-Mediated Diseases

This is a HIA partner technology

Feng Lin, PhD; M.G. Finn, PhD

The complement system is emerging as a new target for treating many diseases. For example, Eculizumab, a humanized monoclonal antibody against complement component 5 (C5), has been approved for paroxysmal nocturnal hemoglobinuria (PNH) in which patient erythrocytes are lysed by complement.


AZ Airway

AZ Airway

This is a HIA partner technology

Rafi Avitsian, MD; Andrew Zura, MD

The AZ Airway provides the ability to ventilate supraglottically and/or infraglottically in a single device.
 


Bone Prep

Bone Prep

This is a HIA partner technology

Joseph Iannotti, MD

The invention is a system of multiple devices and a set of methods that can be used to enhance the short term structural properties of cancellous bone.


BrainFORCE mTBI Screening tool

BrainFORCE mTBI Screening tool

This is a HIA partner technology

Alexander Dromerick, MD; Peter Lum, PhD; Rochelle Tractenberg, PhD

The BrainFORCETM mTBI Screening tool is a rapid assessment test (<10 min) designed to be used in the field (athletic or battle) as the first in battery of tests to diagnose mTBI.


Cannula Design for Improved Proximal Venous Drainage and Distal Arterial Perfusion

Cannula Design for Improved Proximal Venous Drainage and Distal Arterial Perfusion

This is a HIA partner technology

Usman Ahmad, MD; Michael Z. Tong, MD

A cannula for peripheral venous cannulation during ECMO procedures (Extracorporeal membrane oxygenation).


Previous 1 2 3 4 5  ... Next 

Get In Touch With Us